Business
Waverley Pharma Provides Market Update and Fiscal 2018 Preliminary Revenue
Waverley Pharma Provides Market Update and Fiscal 2018 Preliminary Revenue Canada ...
About this update from Waverley Pharma, Inc.
[{"type":"text","content":"\n\n\n\nWaverley Pharma Provides Market Update and Fiscal 2018 Preliminary Revenue\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, March 11, 2019\n\n\n\nWINNIPEG, March 11, 2019 /CNW/ - Waverley Pharma Inc. (\"Waverley Pharma\" or the \"Company\") (TSXV:WAVE), an emerging Canadian pharmaceutical company, today reported unaudited preliminary net revenue for the fourth quarter and full 2018 fiscal year. All amounts referenced herein are in Canadian dollars. Estimated net revenue is $200,000 for the quarter ended December 31, 2018, and the year ended December 31, 2018. The estimated revenue is from sales of two generic oncology products, temozolomide and capecitabine, in the United Kingdom.   \nYear Ended December 31, 2018 Highlights:\nFiled Marketing Authorization Applications in the United States and select European countries in the first half of fiscal 2018 for two anti-cancer injectable generic products; Appointed new CEO, Dr. Theron (Ted) Odlaug, in July 2018; Acquired two generic oncology products, temozolomide and capecitabine, and initiated sales in the United Kingdom in the fourth quarter of fiscal 2018; Preliminary net revenue estimate for the quarter and year ended December 31, 2018 is $200,000.About Waverley Pharma \nWaverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of effective and affordable cancer therapeutics in the EU and North American market. The Company has two generic oncology products at the regulatory filing stage, and is currently marketing two additional generic oncology products, temozolomide and capecitabine, in the United Kingdom. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. For more information on Waverley Pharma please visit www.waverleypharma.com. \nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accu...